
Helping ease your transition to the new CMS guidelines
Spectra Laboratories has developed a Patient Assessment and Plan of Care report to assist you in the implementation of the new Centers for Medicare and Medicaid (CMS) guidelines1:
- Initial/monthly patient assessment
- Comprehensive patient assessment
- Patient-centric plan of care
Spectra's Patient Assessment and Plan of Care report helps you incorporate the essential CMS requirements into your clinical practice:
- Provision for input by interdisciplinary team members, including patient, nurse, physician, social worker and dietitian, is automatically included in the report
- CMS interpretive guidance outcome standards and KDOQI guidelines are included to assist you in developing the desired outcome for each patient
- Laboratory values collected for each patient within the previous three months are provided for trending purposes
- Patient-specific conditions, symptoms, and diagnoses can be selected by simply checking the boxes that apply to each patient
- Text fields are provided for you to add additional comments pertaining to each patient
To download the Patient Assessment and Plan of Care Report, click here
To download frequently asked questions and answers regarding the Patient
Assessment and Plan of Care Report click here
Contact your Spectra Sales Representative today to learn more about implementing this new report into your clinical practice.
*You must have an account user name and password to access the patient assessment and plan of care report. Contact Spectra's Customer Service department to obtain login access:
800-433-3773 (Milpitas, CA)
800-522-4662 (Rockleigh, NJ)
The new Centers for Medicare and Medicaid Services (CMS) guidelines are available at:
http://www.cms.hhs.gov/cfcsandcops/downloads/esrdfinalrule0415.pdf.
1 U.S. Department of Health and Human Services. Centers for Medicare and Medicaid Services. 2008; Medicare and Medicaid Programs: Conditions for Coverage for End-Stage Renal Disease Facilities. 42 CFR Parts 405, 410, 413, 414, 488, and 494.